Small molecule · Inhibitor of BRD2, BRD3 and BRD4 · developed by Novartis Pharmaceuticals
Pelabresib is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins. It binds the acetylated lysine recognition motifs of BET bromodomains, preventing their interaction with acetylated histones and thereby disrupting chromatin remodeling and gene expression. It is being studied in hematologic malignancies and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06401356 | Phase 3 | Hematologic Malignancy | Recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced MalignanciesHematologic MalignancySolid Tumor
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →